GlassScriptPhysician profile
Caroline Pyle
NPI 1285274977
$1,708.45
in general payments reported to CMS, 2019-2025
22 companies · $898 in 2025
The $898 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $169 · 2023: $139 · 2024: $73.33 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.02 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $652.46 | 2021-2025 | Datroway, Airsupra, Imfinzi |
| Janssen Biotech, INC. | $214.77 | 2021-2025 | Rybrevant, Carvykti |
| Genzyme Corporation | $146.88 | 2022 | |
| Amgen INC. | $133.40 | 2021-2023 | Kyprolis, Blincyto |
| Daiichi Sankyo INC. | $111.03 | 2021 | |
| Tersera Therapeutics LLC | $46.01 | 2023-2025 | Zoladex |
| Merck Sharp & Dohme LLC | $43.74 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $43.17 | 2025 | |
| Genentech USA, INC. | $41.06 | 2025 | Ocrevus Zunovo, Venclexta |
| Abbvie INC. | $37.34 | 2022-2025 | |
| Pfizer INC. | $36.33 | 2024-2025 | |
| Lilly USA, LLC | $28.17 | 2023 | Retevmo, Jaypirca |
| Astellas Pharma US INC | $23.31 | 2025 | Xospata |
| Mirati Therapeutics, INC. | $18.98 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $18.49 | 2025 | Monoferric |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shorla Oncology INC. | $18.24 | 2025 | |
| Gilead Sciences, INC. | $17.70 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $16.96 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $16.63 | 2025 | Somatuline Depot, Onivyde |
| Seagen INC. | $15.84 | 2021 | |
| Emd Serono, INC. | $14.22 | 2025 | |
| Eisai INC. | $13.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.